In Brief: Cardiac Pacemakers, Inc.
This article was originally published in The Gray Sheet
Executive SummaryCardiac Pacemakers, Inc.: Guidant unit plans to begin shipments of its Vigor DR and SR adaptive rate pulse generators the week of June 26 following receipt of FDA premarket approval. The dual-chamber DR will list for $7,295 while the single-chamber SR will sell for $6,295, the firm says. The pacer systems "use an advanced accelerometer technology to monitor the patient's physical activity and provide rate modulation to meet the patient's needs." FDA's Circulatory System Devices Panel unanimously recommended approval of the products May 9 ("The Gray Sheet" May 15, p. 10)...
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.